Zoetis Inc. $ZTS Shares Sold by Nilsine Partners LLC

Nilsine Partners LLC lessened its holdings in Zoetis Inc. (NYSE:ZTS) by 85.2% in the 4th quarter, Holdings Channel.com reports. The firm owned 5,061 shares of the company’s stock after selling 29,215 shares during the quarter. Nilsine Partners LLC’s holdings in Zoetis were worth $637,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Three Seasons Wealth LLC raised its stake in shares of Zoetis by 9.4% during the 4th quarter. Three Seasons Wealth LLC now owns 9,781 shares of the company’s stock worth $1,231,000 after buying an additional 838 shares during the period. Fulcrum Capital LLC grew its stake in Zoetis by 5.5% in the 4th quarter. Fulcrum Capital LLC now owns 63,113 shares of the company’s stock valued at $7,941,000 after acquiring an additional 3,266 shares during the period. Meyer Handelman Co. increased its holdings in Zoetis by 13.8% in the 4th quarter. Meyer Handelman Co. now owns 6,771 shares of the company’s stock worth $852,000 after acquiring an additional 823 shares in the last quarter. Rockland Trust Co. increased its holdings in Zoetis by 2,055.2% in the 4th quarter. Rockland Trust Co. now owns 148,557 shares of the company’s stock worth $18,691,000 after acquiring an additional 141,664 shares in the last quarter. Finally, Birch Financial Group LLC raised its position in Zoetis by 5.0% during the fourth quarter. Birch Financial Group LLC now owns 2,999 shares of the company’s stock worth $377,000 after acquiring an additional 142 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ZTS. Piper Sandler reaffirmed a “neutral” rating and set a $135.00 price objective (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. BTIG Research restated a “buy” rating and set a $160.00 price target on shares of Zoetis in a research report on Thursday, February 26th. Barclays began coverage on shares of Zoetis in a research note on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price target on the stock. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Finally, UBS Group set a $136.00 target price on Zoetis in a report on Thursday, January 29th. Six analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $152.91.

Zoetis Stock Performance

NYSE:ZTS opened at $117.83 on Friday. The company has a market cap of $49.74 billion, a P/E ratio of 19.57, a P/E/G ratio of 1.79 and a beta of 0.98. Zoetis Inc. has a twelve month low of $113.29 and a twelve month high of $172.23. The company’s 50-day moving average price is $122.84 and its 200-day moving average price is $128.42. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. During the same quarter in the prior year, the company earned $1.40 EPS. Zoetis’s revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.